106-120 of 847
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Hamid Abuwarda, PhD, BS
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Sharon Sha, MD, MS
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
Ryan Quigley
- advertisement
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's RoundtableLinking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Stephen Wong, PhD
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiersLUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
- advertisement
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
On the Frontlines of Multiple SclerosisAdvancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
Tirisham V. Gyang, MD
Gates B. Colbert, MD
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
On the Frontlines of Multiple SclerosisPrevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Vikram V. Bhise, MD
